Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Cai, now 46, was diagnosed with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, back in 2019. As one of the most ...